The double-edged ocular immune response: The cogan lecture

Investigative Ophthalmology and Visual Science

Volumn 41, Issue 11, 2000, Pages 3243-3248

  Whitcup, S M ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EYE; HUMAN; IMMUNE RESPONSE; MEDICAL RESEARCH; PRIORITY JOURNAL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMAL; ANTIBODY FORMATION; ANTIVIRAL AGENTS; AWARDS AND PRIZES; CYTOMEGALOVIRUS RETINITIS; EYE; FLORIDA; HUMAN; IMMUNE SYSTEM; KERATOCONJUNCTIVITIS SICCA; SOCIETIES, SCIENTIFIC; UVEITIS;

EID: 0033781833     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Complications of chronic cyclitis
2. Immunologically privileged sites
3. Immunologic privilege of the eye
4. Etiology of uveitis. A clinical study of 562 cases
5. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocortisone: Compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis
6. Effects of pituitary adrenocorticotropic hormone (ACTH) therapy in ophthalmologic conditions
7. Effect of ACTH on certain inflammatory diseases of the eye
8. The initiating stimuli for uveitis
9. Murine endotoxin-induced uveitis, but not immune complex-induced uveitis, is dependent on the IL-8 receptor homolog
10. CXC chemokine GRO is essential for neutrophil infiltration in LPS-induced uveitis in rabbits
11. Mechanisms of intraocular inflammation
12. Chemokines in acute anterior uveitis
13. Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats
14. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
15. Endothelial leukocyte adhesion molecule-1 in endotoxin-induced uveitis
16. Monoclonal antibody against CD11b/CD18 inhibits endotoxin-induced uveitis
17. Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis
18. Monoclonal antibodies against CD54 (ICAM-1) and CD11a (LFA-1) prevent and inhibit endotoxin-induced uveitis
19. Blocking both E-selectin and P-selectin inhibits endotoxin-induced leukocyte infiltration into the eye
20. Digital video imaging of leukocyte migration in the iris: Intravital microscopy in a physiological model during the onset of endotoxin-induced uveitis
21. Blocking ICAM-1 (CD54) and LFA-1 (CD11a) inhibits experimental allergic conjunctivitis
22. Expression of cell adhesion molecules in posterior uveitis
23. Expression of cell adhesion molecules in corneal graft failure
24. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases
25. Interleukin-2-recepttor blockade with daclizumab to prevent acute rejection in renal transplantation
26. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial
27. Conjunctival inflammation in non-Sjogren's and Sjogren's syndrome keratoconjunctivitis sicca
28. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease
29. A prospective study of the ophthalmologic findings in the acquired immunodeficiency syndrome
30. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS
31. Retinal manifestations of the acquired immune deficiency syndrome
32. Ophthalmic manifestations of HIV infection
33. Ocular disorders associated with a new severe acquired immune deficiency syndrome
34. Progression rates of CMV retinopathy in ganciclovir-treated and untreated patients
35. Studies of the ocular complications of AIDS, mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis
36. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: Prevalence, natural history, and response to ganciclovir therapy
37. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial
38. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection
39. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
40. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis
41. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts
42. Spontaneous and sustained resolution of CMV retinitis in patients receiving highly active antiretroviral therapy
43. Discontinuation of anti-cytomegalovirus therapy in patients with HIV infection and cyto-megalovirus retinitis
44. Regression of cytomegalovirus retinitis associated with protease inhibitor treatment in patients with AIDS
45. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in httman immunodeficiency virus-infected patients
46. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy
47. Discontinuing anticytomegalovirus therapy in patients with immume reconstitution after combination antiretroviral therapy
48. AIDS and ophthalmology: A period of transition
49. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
50. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: A new syndrome
51. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis
52. Cystoid macular edema due to cytomegalovirus in a patient with acquired immunodeficiency virus
53. Treatment of immune recovery vitritis with local steroids
54. Elevation of laser flare photometry in patients with cytomegalovirus retinitis and AIDS
55. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: A geographical view of immune reactivity
56. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease
57. HIV combination therapy: Partial immune restitution unmasking latent cryptococcal infection